Pfizer (NYSE:PFE) recently posted its Q4 results, which were slightly above the street estimates. The company's overall sales grew 5%, while adjusted earnings per share was up 3%. As expected, the company saw higher sales for Ibrance, Eliquis, and Xeljanz, which aided the overall earnings growth....
Pfizer (NYSE:PFE) recently posted its Q4 results, which were slightly above the street estimates. The company's overall sales grew 5%, while adjusted earnings per share was up 3%. As expected, the company saw higher sales for Ibrance, Eliquis, and Xeljanz, which aided the overall earnings growth....
Share this Article
Recommended